SVNT: Summary for Savient Pharmaceuticals Inc - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 3:46am EST - Canadian Markets open in 5 hours and 44 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Savient Pharmaceuticals Inc. (SVNT)

On Nov 24: 13.25 USD 0.00 (0.00%)

MORE ON SVNT

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Savient Pharmaceuticals Inc (NGM:SVNT) Delayed quote data

Last Trade:	13.25 USD
Trade Time:	Nov 24
Change:	0.00 (0.00%)
Prev Close:	13.25
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	28.13

Day's Range:	N/A - N/A
52wk Range:	3.06 - 16.62
Volume:	0
Avg Vol (3m):	1,924,320
Market Cap:	882.79M
P/E (ttm):	N/A
EPS (ttm):	-0.78
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add SVNT to Portfolio

Download Data

HEADLINES

•	SAVIENT PHARMACEUTICALS INC Financials
	EDGAR Online Financials (Fri, Nov 13)

•	SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
	EDGAR Online (Mon, Nov 9)

•	New Star Analyst Rankings for Savient Pharmaceuticals Inc
	StarMine (Thu, Nov 5)

•	Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
	PRNewswire (Wed, Nov 4)

•	Q3 2009 Savient Pharmaceuticals, Inc. Earnings Release - After Market Close
	CCBN (Wed, Nov 4)

•	Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009
	PRNewswire (Wed, Oct 28)

•	SAVIENT PHARMACEUTICALS INC Files SEC form 8-K/A, Costs Associated with Exit or Disposal Activities
	EDGAR Online (Thu, Oct 22)

•	Wedbush Morgan Biotech Analyst Sees Access To Capital Increasing Again For Small Cap Firms
	Wall Street Transcript (Tue, Oct 20)

•	SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Thu, Oct 15)

•	Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
	PRNewswire (Thu, Oct 15)

More Headlines for SVNT...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	1.3
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Savient Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products that target unmet medical needs.

Full Company Profile

Add to Portfolio

Email to a Friend

•